Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Chris Buys
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Applied DNA Sciences, Inc. ... anti-counterfeiting technology and product authentication solutions, will host a ... its fiscal third quarter results. The Quarterly Report on ... the end of the day on Monday August 11, ... host a conference call beginning at 9:00 A.M. Eastern ...
(Date:8/1/2014)... , Aug. 1. 2014 As one of ... 2014 AACC Annual Meeting & Clinical Lab Expo is ... patient care are introduced to the healthcare world. This ... Expo,s 650 exhibitors will include the latest diagnostic technology ... Advances in smartphones and biosensors have enabled the development ...
(Date:8/1/2014)... , August 1, 2014 According ... Research "Biophotonics Market - Global Industry Analysis, Size, Share, ... was valued at USD 25.16 billion in 2013, which ... growing at a CAGR of 10.4% from 2014 to ... at  http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate ...
(Date:8/1/2014)... Aug. 1, 2014 Cambrex Corporation (NYSE: ... 30, 2014. Highlights , Second ... in the same period last year. , Second quarter ... in the same period last year (see table at the ... guidance increased, excluding the impact of foreign currency, to between ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... Medical Technology. Inc.,has been awarded a five-year contract ... VHA Inc. and the University HealthSystem,Consortium (UHC), two ... The agreement makes Liftaem(TM) available to more ... "By using proper equipment such,as Liftaem(TM), hospitals not ...
... 12 VIA Pharmaceuticals,(Nasdaq: VIAP ), ... of,compounds for the treatment of cardiovascular disease, ... board. Joining the clinical advisory,board,s chair, Marc ... Medical School, and Senior Physician, Brigham & ...
... Breakthrough Pain Associated with Chronic Pain Conditions in ... ... Around-the-Clock, FRAZER, Pa., Nov. 12 Cephalon, Inc. (Nasdaq:,CEPH) ... the U.S. Food and Drug Administration (FDA) seeking approval to,market FENTORA(R) ...
Cached Biology Technology:Smart Medical Technology, Inc. Awarded Novation Contract for Ground-breaking Liftaem(TM) System that Aids Lifting and Transferring Patients 2VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 2VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 3VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 4Cephalon Submits Supplemental New Drug Application for FENTORA 2Cephalon Submits Supplemental New Drug Application for FENTORA 3Cephalon Submits Supplemental New Drug Application for FENTORA 4Cephalon Submits Supplemental New Drug Application for FENTORA 5Cephalon Submits Supplemental New Drug Application for FENTORA 6Cephalon Submits Supplemental New Drug Application for FENTORA 7
(Date:8/1/2014)... 10,000 reptile species have been recorded into the ... reptile species and classification, making the reptile species ... world, alongside bird and fish species. , For ... mark the year that reptiles would become the ... include snakes, lizards, turtles, crocodiles, tuataras and amphisbaenians. ...
(Date:8/1/2014)... of the UC Davis Center for Neuroscience and ... Science and Engineering Faculty Fellowship from the U.S. ... will support new work on learning and memory ... , The new project aims to connect neural ... in the cortex and hippocampus, brain regions that ...
(Date:8/1/2014)... of marine mammals have officially named a species ... Sousa sahulensis , according to the Wildlife Conservation ... describing the newly named species is the culmination ... available historical records, physical descriptions, and genetic data ... ranging from the coast of West Africa to ...
Breaking Biology News(10 mins):Reptile Database surpasses 10,000 reptile species 2Reptile Database surpasses 10,000 reptile species 3Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... African Americans are four to five times more likely to ... kidney failure have an increased risk of developing kidney failure, ... skewed risk between races. Previous studies identified variants in a ... gene creates a protein that is a component of HDL, ...
... innovative analysis of how social media can affect the ... by a scientist at Penn State University studying attitudes ... of biology, studied how users of Twitter -- a ... about a new vaccine. He then tracked how the ...
... Now computers are at it again, but this ... itself. An interdisciplinary team of scientists at Vanderbilt ... taken a major step toward this goal by demonstrating ... a biological system and derive the basic mathematical equations ...
Cached Biology News:Better ways to predict kidney disease risk for African Americans 2Better ways to predict kidney disease risk for African Americans 3Twitter data used to track vaccination rates and attitudes 2Twitter data used to track vaccination rates and attitudes 3Twitter data used to track vaccination rates and attitudes 4Robot biologist solves complex problem from scratch 2Robot biologist solves complex problem from scratch 3
... a platform for fully automated systems for ... easily be configured for applications ranging from ... allows closed loop screening, which means it ... generating, cherry picking and follow up studies ...
... Vivaclear centrifugal filters are disposable microfiltration devices for ... in the range 100 l to 500 l. ... accepting 2.2 ml centrifuge tubes. Product Features: ... size Low hold up volume ( ...
... The Caliper Prelude Workstation fully ... as solvent addition, extraction, sample transfer, ... on-line HPLC, and UV detection. The ... compliance with 21 CFR Part 11. ...
... Use in any standard fixed-angle microcentrifuge ... g.,Spin- centrifuge tube filters consist ... a centrifuge tube. They filter by ... HPLC sample preparation, removal of cells ...
Biology Products: